Soucasny pohled na problematiku rezistence kmenu Helicobacter pylori vuci antimikrobnim lecivum
[Current perspective of the resistance of Helicobacter pylori strains to antimicrobial drugs]
Language Czech Country Czech Republic Media print
Document type Journal Article, Review
PubMed
21243598
- MeSH
- Anti-Bacterial Agents administration & dosage MeSH
- Drug Resistance, Bacterial MeSH
- Helicobacter pylori drug effects MeSH
- Helicobacter Infections drug therapy microbiology MeSH
- Proton Pump Inhibitors therapeutic use MeSH
- Clarithromycin administration & dosage MeSH
- Drug Therapy, Combination MeSH
- Levofloxacin MeSH
- Humans MeSH
- Metronidazole administration & dosage MeSH
- Ofloxacin administration & dosage MeSH
- Check Tag
- Humans MeSH
- Publication type
- Journal Article MeSH
- Review MeSH
- Names of Substances
- Anti-Bacterial Agents MeSH
- Proton Pump Inhibitors MeSH
- Clarithromycin MeSH
- Levofloxacin MeSH
- Metronidazole MeSH
- Ofloxacin MeSH
A significant increase in H. pylori resistance to clarithromycin and metronidazole has been proven in both children and adults. Clarithromycin with resistance over 20 % and metronidazole with resistance over 40 % are not recommended for treating H. pylori infection. Preferred treatment regimens were designed to reflect the current situation. The classical regimen PPI + AMO + CLA (MET) can be used in cases where the resistance against CLA and MET is lower than stated above. In the opposite case, a combination of PPI + AMO + levofloxacin (or rifabutin, or furazolidone) must be used. In many countries, this regimen is already the first-choice treatment. The 4-combination with bismuth is suitable in case of 3-combination treatment failure, or in patients allergic to penicillin.
